Cost-effectiveness of intravenous proton pump inhibitors in high-risk bleeders

Sander Veldhuyzen van Zanten MD FRCPC


There is unequivocal evidence that proton pump inhibitors (PPIs) are currently the most effective acid suppressive agents available. Intravenous (IV) formulations have been developed, although only IV pantoprazole is available in Canada. In patients presenting with serious upper gastrointestinal (GI) bleeding due to duodenal or gastric ulcers, it has always been believed that IV administration of acid-lowering agents would improve clinical outcomes. The reason behind this thinking is twofold. First, there is in vitro evidence that formed clots are more stable at or near neutral pH (1). Second, by administering the agent intravenously, suppression of acid production is achieved much more quickly, thereby promoting more rapid healing of the ulcer and reducing the risk of persistent or recurrent bleeding. Interestingly and surprisingly, however, the data for intravenous H₂-blockers have been disappointing (2). This failure to demonstrate clinical benefit has never been fully explained.

Over the past few years, several studies have been published that suggest that IV PPIs may reduce the incidence of rebleeding and the requirement for either blood transfusions or surgical intervention. Furthermore, a decrease in the length of hospital stay can also be expected and would result in cost savings.

Using the data from a pivotal Hong Kong study that showed the benefit of IV PPI use (3), and incorporating Canadian health care cost data and the best estimates from the literature about important outcomes (length of hospital stay and rates of rebleeding, surgery and death), Enns and colleagues performed a very comprehensive cost-effectiveness analysis of the use of IV pantoprazole. In their model, the first approach was to administer IV PPIs to all patients presenting to the emergency room with evidence of serious upper GI bleeding, including melena or hematemesis. The second approach was to withhold IV PPIs from all patients and provide standard treatment, with endoscopic therapy if there were high-risk stigmata for bleeding, such as signs of active bleeding, a visible vessel or overlying clot.

The analysis had a 60-day horizon and was based on payments from a third-party perspective, such as Provincial Ministries of Health. The following outcomes were used in the IV PPI group: endoscopic treatment was given if a high-risk ulcer was identified, the IV PPI was continued, patients were then monitored and failures were treated with either repeat endoscopy or surgery. In the control group, no IV PPIs were given, but therapeutic endoscopy was performed if high-risk stigmata were seen. Patients were again followed and failures were treated either surgically or by repeat endoscopies. It was assumed that such patients would receive a 30-day treatment with a standard oral PPI regimen. Similarly, in the IV PPI group, patients who did not have high-risk stigmata received a 30-day course of oral PPIs. Using published data on the success rates of therapeutic endoscopy, IV PPIs, repeat endoscopy and surgery, it was convincingly shown that the use of IV PPI was cost-effective. Using a hypothetical cohort of 1000 patients, the use of IV PPI resulted in a mean savings of $20,700 and the prevention of 37 episodes of rebleeding. It is important to stress that it was assumed in the model that all patients would undergo endoscopy on average 24 h after presentation. This timeframe certainly makes clinical sense and is in keeping with the Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE), which showed that 76% of patients underwent endoscopy within 24 h (4). The use of IV PPIs remained cost-effective when several of the outcomes were varied in a sensitivity analysis.

This carefully conducted study supports the use of IV PPIs in patients who present to the emergency department with significant upper GI bleeding. A recent Canadian cost-effectiveness analysis by Barkun et al (5) confirmed that high-dose IV PPIs are more cost-effective than either high-dose oral PPIs or placebo. The cumulative evidence therefore certainly supports the use of IV PPIs in patients presenting with significant upper GI bleeding.

In practice, a few other issues need to be considered. First of all, from a hospital prospective, IV PPIs may be overutilized. In
the study by Enns et al, it was assumed that patients presented with “serious GI bleeding”, but this is a loosely used term in the emergency room setting. Clearly, a patient who is vomiting bright red blood or is having active melena is different from a patient who presents with coffee ground emesis and normal hemoglobin. Physicians performing endoscopies are very aware of this issue. In reality, the decision to start PPIs, however, is often not taken by the endoscopist but by the referring physician. The other important situation in which savings are possible is the discontinuation of IV PPIs in patients who are proven not to require them, including those without high-risk lesions at endoscopy. Such patients could readily be switched to oral PPIs, if necessary, at twice the standard dosage.

In summary, IV PPIs now are the accepted standard of care in patients presenting with serious upper GI bleeding. They should be continued for up to 72 h in patients who have high-risk endoscopic findings. Importantly, many patients who turn out to have less severe endoscopic lesions can and should be switched to oral PPIs, thereby avoiding the unnecessary use of the more expensive IV formulation.

REFERENCES
Submit your manuscripts at http://www.hindawi.com